719 related articles for article (PubMed ID: 18695909)
1. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.
Ory B; Heymann MF; Kamijo A; Gouin F; Heymann D; Redini F
Cancer; 2005 Dec; 104(11):2522-9. PubMed ID: 16270320
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
Onn A; Isobe T; Wu W; Itasaka S; Shintani T; Shibuya K; Kenji Y; O'reilly MS; Fidler IJ; Herbst RS
Clin Cancer Res; 2004 Dec; 10(24):8613-9. PubMed ID: 15623645
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Yano S; Zhang H; Hanibuchi M; Miki T; Goto H; Uehara H; Sone S
Clin Cancer Res; 2003 Nov; 9(14):5380-5. PubMed ID: 14614023
[TBL] [Abstract][Full Text] [Related]
6. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
Zarogoulidis K; Boutsikou E; Zarogoulidis P; Eleftheriadou E; Kontakiotis T; Lithoxopoulou H; Tzanakakis G; Kanakis I; Karamanos NK
Int J Cancer; 2009 Oct; 125(7):1705-9. PubMed ID: 19521984
[TBL] [Abstract][Full Text] [Related]
7. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
Peng H; Sohara Y; Moats RA; Nelson MD; Groshen SG; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2007 Oct; 67(19):9346-55. PubMed ID: 17909043
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
[TBL] [Abstract][Full Text] [Related]
9. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides.
Weerasinghe P; Garcia GE; Zhu Q; Yuan P; Feng L; Mao L; Jing N
Int J Oncol; 2007 Jul; 31(1):129-36. PubMed ID: 17549413
[TBL] [Abstract][Full Text] [Related]
11. Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.
Henk HJ; Kaura S; Teitelbaum A
J Med Econ; 2012; 15(1):195-204. PubMed ID: 22175657
[TBL] [Abstract][Full Text] [Related]
12. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.
Hermann TW; Yen WC; Tooker P; Fan B; Roegner K; Negro-Vilar A; Lamph WW; Bissonnette RP
Lung Cancer; 2005 Oct; 50(1):9-18. PubMed ID: 15993980
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
14. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
Hu Y; Bebb G; Tan S; Ng R; Yan H; Sartor JR; Mayer LD; Bally MB
Clin Cancer Res; 2004 Nov; 10(22):7662-70. PubMed ID: 15569999
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells.
Chang JW; Hsieh JJ; Shen YC; Yeh KY; Wang CH; Li YY; Hsu T
Cancer Lett; 2009 Jun; 278(1):17-26. PubMed ID: 19233551
[TBL] [Abstract][Full Text] [Related]
18. Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
Nagao S; Hattori N; Fujitaka K; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Haruta Y; Murai H; Kohno N
Hiroshima J Med Sci; 2011 Mar; 60(1):7-9. PubMed ID: 21675041
[TBL] [Abstract][Full Text] [Related]
19. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
Shalinsky DR; Brekken J; Zou H; Bloom LA; McDermott CD; Zook S; Varki NM; Appelt K
Clin Cancer Res; 1999 Jul; 5(7):1905-17. PubMed ID: 10430098
[TBL] [Abstract][Full Text] [Related]
20. [Inhibitory effect of bcl-2 antisense oligodeoxynucleotides on growth of human lung carcinoma xenograft in nude mice].
He DM; Zhang H
Ai Zheng; 2006 Jan; 25(1):40-4. PubMed ID: 16405747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]